Advanced search
1 file | 225.66 KB Add to list

Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study

Author
Organization
Keywords
TNF-alpha, Hand Osteoarthritis, DMARDs (biologic), TRIAL

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 225.66 KB

Citation

Please use this url to cite or link to this publication:

MLA
Wittoek, Ruth, et al. “Immunoscintigraphic Detection of Tumour Necrosis Factor by Radiolabelled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis : A Proof-of-Concept Study.” ANNALS OF THE RHEUMATIC DISEASES, vol. 77, no. 2, 2018, pp. 310–11, doi:10.1136/annrheumdis-2016-210354.
APA
Wittoek, R., Carron, P., Lambert, B., Meersseman, P., Verbruggen, A., Van den Bosch, F., & Elewaut, D. (2018). Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study. ANNALS OF THE RHEUMATIC DISEASES, 77(2), 310–311. https://doi.org/10.1136/annrheumdis-2016-210354
Chicago author-date
Wittoek, Ruth, Philippe Carron, Bieke Lambert, Paulien Meersseman, August Verbruggen, Filip Van den Bosch, and Dirk Elewaut. 2018. “Immunoscintigraphic Detection of Tumour Necrosis Factor by Radiolabelled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis : A Proof-of-Concept Study.” ANNALS OF THE RHEUMATIC DISEASES 77 (2): 310–11. https://doi.org/10.1136/annrheumdis-2016-210354.
Chicago author-date (all authors)
Wittoek, Ruth, Philippe Carron, Bieke Lambert, Paulien Meersseman, August Verbruggen, Filip Van den Bosch, and Dirk Elewaut. 2018. “Immunoscintigraphic Detection of Tumour Necrosis Factor by Radiolabelled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis : A Proof-of-Concept Study.” ANNALS OF THE RHEUMATIC DISEASES 77 (2): 310–311. doi:10.1136/annrheumdis-2016-210354.
Vancouver
1.
Wittoek R, Carron P, Lambert B, Meersseman P, Verbruggen A, Van den Bosch F, et al. Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study. ANNALS OF THE RHEUMATIC DISEASES. 2018;77(2):310–1.
IEEE
[1]
R. Wittoek et al., “Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study,” ANNALS OF THE RHEUMATIC DISEASES, vol. 77, no. 2, pp. 310–311, 2018.
@article{8522790,
  author       = {{Wittoek, Ruth and Carron, Philippe and Lambert, Bieke and Meersseman, Paulien and Verbruggen, August and Van den Bosch, Filip and Elewaut, Dirk}},
  issn         = {{0003-4967}},
  journal      = {{ANNALS OF THE RHEUMATIC DISEASES}},
  keywords     = {{TNF-alpha,Hand Osteoarthritis,DMARDs (biologic),TRIAL}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{310--311}},
  title        = {{Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis : a proof-of-concept study}},
  url          = {{http://dx.doi.org/10.1136/annrheumdis-2016-210354}},
  volume       = {{77}},
  year         = {{2018}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: